Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment - Long-term Efficacy and Safety Interim Data of the RELIANCE Registry

Joerg Henes¹, Jasmin B. Kuemmerle-Deschner², Tobias Krickau³, Tilmann Kallinich⁴, Frank Dressler⁵, Gerd Horneff⁶, Florian Meier⁷, Ivan Foeldvari⁸, Frank Weller-Heinemann⁹, Birgit Kortus-Goetze¹⁰, Markus Hufnagel¹¹, Juergen Rech¹², Prasad T. Oommen¹³, Julia Weber-Arden¹⁴ and Norbert Blank¹⁵, ¹Center for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases (INDIRA), University Hospital Tübingen, Tübingen, Germany, ²Department of Pediatrics, Division of Pediatric Rheumatology, University Hospital Tübingen, Tübingen, Germany, ³Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Pediatrics, Erlangen, Germany, ⁴Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁵Division of Pediatric Pneumology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany, ⁶Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁷Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany, and Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine and Pharmacology TMP, Frankfurt, Germany, ⁸Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁹Klinikum Bremen-Mitte, Prof. Hess Kinderklinik, Bremen, Germany, ¹⁰Division of Nephrology, University of Marburg, Marburg, Germany, ¹¹Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹²University Clinic Erlangen, Erlangen, Germany, ¹³Clinic of Pediatric Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ¹⁴Novartis Pharma GmbH, Nuernberg, Germany, ¹⁵Rheumatology, University Hospital Heidelberg, Heidelberg, Germany

Meeting: ACR Convergence 2022

Keywords: Autoinflammatory diseases, Biologicals, FMF, Innate Immunity Rheumatic Disease, longitudinal studies

Session Information

Date: Saturday, November 12, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Familial Mediterranean fever (FMF) is a chronic disease characterized by recurrent episodes of fever and serositis, with a risk of severe complications (e. g. amyloidosis). Treatment of FMF according to EULAR recommendations aims to control acute relapses and subclinical inflammation and improve patients’ quality of life. Clinical data suggest that inhibition of interleukin-1β with canakinumab (CAN) is effective in controlling and preventing relapses in FMF patients.

The present study investigates the long-term efficacy and safety of CAN in routine clinical practice in pediatric (age ≥2 years) and adult FMF patients.

Methods: RELIANCE is a prospective, non-interventional, multicenter observational study in Germany with a follow-up period of up to seven years. Patients with a clinically confirmed diagnosis of FMF who routinely receive CAN will be enrolled in the study. At the time of study inclusion and at six-months intervals, the following parameters will be recorded: Disease activity (physician assessment), fatigue and impact on social life (patient assessment), inflammatory markers and the Auto-Inflammatory Diseases Activity Index (AIDAI) score.

Results: This interim analysis of FMF patients (N=74) enrolled through December 2021 includes data from baseline through the 24-months visit. The mean age in this cohort was 25 years (2-61 years). The proportion of female patients was 51% (N=38). At baseline, the median duration of prior CAN treatment was 1.0 years (0-6 years). Patients had been pre-treated with colchicine (71%), canakinumab (77%), anakinra (31%) and tocilizumab (5%). At month 24, approximately 63% of patients were in disease remission by physician assessment, and 67% of patients documented inactive disease in the AIDAI (Table 1).

Mutations were documented in a total of N=57 patients. Most common variants were M694V (9 homozygous [hoz], 10 compound heterozygous [hec], 12 heterozygous [hez],), V726A (1 hoz, 6 hec, 1 hez), and M680I (1 hoz, 6 hec, 1 hez).

At baseline, N=16 FMF patients were CAN-naive and received a starting dose of median 150 mg CAN (40 mg/kg – 150 mg every 4 weeks). In this subgroup, a total of 12 dose adjustments were made over the course of two years (9 dose increases, 3 dose reductions).

A total of 18 severe adverse events (SAE) were reported, of which 2 (tonsillectomy due to recurrent tonsillitis and tachycardia, patient age: 6 years each) were classified as drug-related.

Conclusion: Interim data from FMF patients in the RELIANCE study, the longest running canakinumab registry, confirm the efficacy and safety of long-term treatment with canakinumab. Dose adjustments during the course of therapy are possible.

Table 1: Evaluation of clinical disease activity and safety aspects of patients with FMF.

Disclosures: J. Henes, Boehringer Ingelheim; J. Kuemmerle-Deschner, AbbVie/Abbott, Novartis, SOBI; T. Krickau, Novartis; T. Kallinich, Roche; F. Dressler, Novartis, AbbVie/Abbott, Mylan, Pfizer; G. Horneff, Roche, Pfizer, Novartis, Merck/MSD, Eli Lilly, AbbVie/Abbott; F. Meier, Novartis; I. Foeldvari, None; F. Weller-Heinemann, None; B. Kortus-Goetze, Novartis; M. Hufnagel, Novartis; J. Rech, Novartis, SOBI, AbbVie/Abbott, Biogen, Bristol-Myers Squibb(BMS), Chugai, GlaxoSmithKlein(GSK), Janssen, Eli Lilly, Merck/MSD, Mylan, Roche, Sanofi, UCB; P. Oommen, Novartis; J. Weber-Arden, Novartis; N. Blank, Novartis, SOBI, Lilly, Pfizer, AbbVie/Abbott, Bristol-Myers Squibb(BMS), Merck/MSD, Actelion, UCB, Boehringer-Ingelheim, Roche.

To cite this abstract in AMA style:

Henes J, Kuemmerle-Deschner J, Krickau T, Kallinich T, Dressler F, Horneff G, Meier F, Foeldvari I, Weller-Heinemann F, Kortus-Goetze B, Hufnagel M, Rech J, Oommen P, Weber-Arden J, Blank N. Patients with Familial Mediterranean Fever (FMF) Under Canakinumab Treatment – Long-term Efficacy and Safety Interim Data of the RELIANCE Registry [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/patients-with-familial-mediterranean-fever-fmf-under-canakinumab-treatment-long-term-efficacy-and-safety-interim-data-of-the-reliance-registry/. Accessed .

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patients-with-familial-mediterranean-fever-fmf-under-canakinumab-treatment-long-term-efficacy-and-safety-interim-data-of-the-reliance-registry/